Martin Reck

@g_mountzios @MartinReck2 @JordiRemon @HendriksLizza @JessicaMenis @RobertoFerrara_ @DrJNaidoo @NReguart @HLinardou @NarjustFlorezMD @JhanelleGray We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/voices/giannis…

😊 🩷 Nice to see friends and colleagues in the #lungcancer community from different continents at #ELCC26. @caliraf @Alfdoc2 @HHorinouchi @MartinReck2 @Tony_Calles @DoctorJSpicer @fred_hirsch @bensolomon1 @NReguart @BalazsHalmosMD @BrendonStilesMD @mollylisc @karenkellymd @ThomasW35874311 @NadalErnest @DrSanjayPopat 😊 🩷 Safe travels ✈️ 💐💐💐Grateful for the wonderful organization between @IASLC and @esmo for an impactful and fun #ELCC26.

Back home from an amazing #ELCC26, I keep reflecting on the true value of scientific meetings: The best science and education comes only among people who are unite by friendship, mutual respect and a common vision: to improve the care of our patients with lung cancer See you all in #ELCC27! @myESMO @IASLC

🆙 #ELCC26 @myESMO @IASLC 🇩🇰 🔥Mini Oral session 2 ☑️KEYNOTE-671: 5 years F/U in non-pCR subgroup 🎯EFS HR 0.69, 5-y rate 42.9% vs. 25.2%, OS immature 🎙️ @MartinReck2 🎙️Chair: Dr. Kersti Oselin @MARIANOPROVENCI 📍NCT03425643 @OncoAlert @Larvol #LCSM

#ELCC26 @MartinReck2 on KN671 exploratory analysis of patients without pCR 5-year EFS 43% vs 25% , HR =0,69, 95%CI 0.57-0.83)

#ELCC26 Day3 Mini Oral @MartinReck2 presented "Exploratory Analysis of Participants Without Pathological Complete Response (pCR) in the KEYNOTE-671 Study of Perioperative Pembrolizumab (Pembro) in Early-Stage #NSCLC After 5 Years of Follow-Up" @IASLC @myESMO

Issue of impact and value Postop immunotherapy in perioperative strategy in NSCLC start to be analyzed @MartinReck2 at #ELCC2026 @OncoAlert

T-2 days until #ELCC26 in Copenhagen🇩🇰 Join myself, @JordiRemon #CaicunZhou & #SarahPilotto to learn about all things KRAS on day 1, led by @MartinReck2 @myESMO #ESMOAmbassadors #ELCC26 @KRASKickers @OncoAlert @CancerCentreIre @cancertrials_ie #LCSM

Always a privilege to listen to one of the true pioneers of immunotherapy in thoracic oncology @MartinReck2 . Inspiring as ever ! @myESMO

I am starting to notice that after 20+ yrs of oncology some of my skills are starting to be as good as that of a top Ortho surgeon!

#GeneralThoracic #CME article from Liberman et al on Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671: #AnnalsCME" target="_blank" rel="nofollow noopener">doi.org/10.1016/j.atho… @JonesDavid2013 @HwakeleeMD @BalazsHalmosMD @NadalErnest @MartinReck2 @DoctorJSpicer

Are you interested for a deep-dive in early stage #NSCLC including perioperative IO/targeted, ADCs and future trial design? Don't miss the @myESMO advanced course in #Athens on 23-24th April chaired by @peters_solange , @ElinardouHelena and myself Register: 👉lnkd.in/due7fgRi Deadline: 18 March 2026 @OncoAlert #some #LCSM

A new therapeutic opportunity is emerging in MTAP-deleted NSCLC using PRMT5 inhibitors. During our Year in Review roundtable with @peters_solange, @MartinReck2 and @charlesrudin, we learned how this new class of drugs may target 10% to 30% of all NSCLC cases. These compounds are also being developed in other solid tumors and are now moving into frontline strategies with chemo and potentially IO. Watch the full roundtable here ⬇️ lungsummit.org/all-sessions/

Just out! Delighted to share some work on (IO) refractory Lung Cancer. Thank you for a fantastic cooped! Feasibility and safety of nintedanib in combination with nivolumab in ... sciencedirect.com/science/articl… #LCSM

How do we best handle progression in EGFR mutant NSCLC? @MartinReck2 linked the frontline selection model from @ZosiaPiotrowska to resistance strategies defined by @RamalingamMD. With 4th generation targets remaining rare the focus shifts to MET alterations. Options for treatment include the use of amivantamab, which was done in the MARIPOSA-2 trial, or the combination of osimertinib and savolitinib as shown here with the SACHI trial. Watch the full talk with @peters_solange and @charlesrudin ➡️ lungsummit.org/targeted-thera…

Toughest debate at #ITCD2026: Italian vs German sensibilities! 🍷🍺

Fantastic discussion at #ITD2026 with Dr @NarjustFlorez on neoadjuvant approaches with targeted therapy. Really inspiring discussion around surgical considerations and different perspectives on NeoAdaura data. #ITCD2026

Dr. @delvysra at #ITCD2026 explains why targeting PD-1 and VEGF holds such promise with bispecific antibodies like ivonescimab and pumitamig now in the clinic. Intriguing efficacy signals and safety seems better than separate antibodies.

IV International Thoracic Cancer Debates #ITCD26. Gran Canaria, Spain. Very proud to participate in this session on #SCLC with excellent experts, Great advances in SCLC. Thanks @delvysra #LCSM @OncoAlert @myESMO @Hospital_FJD @quironsalud @UAM_Madrid @AEACaP #IIS-FJD #Lungcancer

✨What comes first in EGFR-m NSCLC the neo or the adjuvant? Or are we entering the era of both? It was a pleasure presenting this evolving perioperative puzzle at #ITCD2026 in beautiful Gran Canaria 🇮🇨 Exciting times ahead for targeted therapy in early-stage lung cancer!